WO2003061637A1 - Compositions for pulmonary administration - Google Patents

Compositions for pulmonary administration Download PDF

Info

Publication number
WO2003061637A1
WO2003061637A1 PCT/FI2003/000054 FI0300054W WO03061637A1 WO 2003061637 A1 WO2003061637 A1 WO 2003061637A1 FI 0300054 W FI0300054 W FI 0300054W WO 03061637 A1 WO03061637 A1 WO 03061637A1
Authority
WO
WIPO (PCT)
Prior art keywords
corticosteroid
medicament according
inhalation
orazipone
inhalation medicament
Prior art date
Application number
PCT/FI2003/000054
Other languages
French (fr)
Inventor
Pertti Happonen
Elina Serkkola
Erkki Nissinen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Priority to CA002473697A priority Critical patent/CA2473697A1/en
Priority to EP03700322A priority patent/EP1476142A1/en
Priority to US10/502,087 priority patent/US20050143361A1/en
Publication of WO2003061637A1 publication Critical patent/WO2003061637A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the present invention relates to pharmaceutical compositions useful in the treatment of asthma and other respiratory disorders. More particularly, it relates to compositions comprising anti-inflammatory agent orazipone in combination with a ⁇ 2 -adrenoreceptor agonist and/or a corticosteroid.
  • Asthma is currently treated with drugs that can be classified into two classes, namely anti-inflammatory agents and bronchodilators.
  • Anti-inflammatory drugs such as corticosteroids and sodium cromoglycate do not relieve asthma symptoms once they occur, but rather they control the underlying inflammation.
  • One of the drawbacks of anti-inflammatory drugs is that their onset of action is relatively slow. Therefore, patients often do not recognize any immediate therapeutic effects and tend to stop the medication.
  • the acute asthma symptoms can be relieved by bronchodilators such as ⁇ 2 -adrenoreceptor agonists and theophylline.
  • the short- acting inhaled ⁇ 2 -adrenoreceptor agonists e.g.
  • salbutamol and terbutaline are important for an immediate symptomatic asthma relief, while long-acting ⁇ 2 - adrenoreceptor agonists, e.g. salmeterol, formoterol and procaterol, are important for treatment of moderate and severe asthma.
  • long-acting ⁇ 2 - adrenoreceptor agonists e.g. salmeterol, formoterol and procaterol
  • Inhalation has become the primary route of administration in the treatment of asthma and other respiratory diseases. This is because, besides providing direct access to the lungs, medication delivered through the respiratory tract provides rapid and predictable onset of action and requires lower dosages compared to the oral route.
  • Typical delivery systems for inhalable drugs are the pressurized metered-dose inhaler (pMDI) comprising a suspension of fine drug particles in a propellant gas; the dry powder inhaler (DPI) comprising fine drug particles as dry powder typically admixed with coarser carrier or diluent such as lactose, and nebulizer comprising drug in aqueous solution or suspension.
  • pMDI pressurized metered-dose inhaler
  • DPI dry powder inhaler
  • nebulizer comprising drug in aqueous solution or suspension.
  • Inhalable combinations of an anti-inflamma- tory agent and a bronchodilator have been described e.g. in patent publications EP 416950, EP 416951
  • an inhalation medicament comprising, as a combined preparation, orazipone and a ⁇ -adrenoreceptor agonist and/or a corticosteroid, provides improved disease control of asthma and other respiratory disorders.
  • the present invention provides an inhalation medicament comprising orazipone and a ⁇ 2 -adrenoreceptor agonist and/or a corticosteroid as a combined preparation.
  • the present invention also provides a method for treating asthma and other respiratory disorders which comprises the simultaneous, sequential or separate administration of an effective amount of orazipone and a ⁇ 2 -adrenoreceptor agonist and/or a corticosteroid.
  • the present invention also provides an inhaler device containing orazipone and ⁇ 2 -adrenoreceptor agonist and/or a corticosteroid as therapeutically active ingredients for pulmonary administration.
  • the active ingredients of the combination are preferably presented, separately or in admixture, as a pharmaceutical formulation together with one or more pharmaceutically acceptable additive, diluent or carrier.
  • the active ingredients are preferably provided as micronized particles, e.g. having mass median diameter of less than 10 ⁇ m.
  • the medicament is provided in the form of dry inhalation powder comprising the active ingredients in admixture with carrier particles.
  • FIG. 1 shows the effect of budesonide and orazipone and combination thereof on LPS-induced IL-8 production in peripheral blood mononuclear cells.
  • Orazipone or 3-[(4-methylsulfonylphenyl)-methylene]-2,4-pentanedione is a locally acting anti-inflammatory agent that decomposes in the blood circulation.
  • a method for preparing orazipone for the treatment of inflammatory bowel disease is described in European Patent No. 440324 Bl.
  • a powdered inhalation composition of orazipone for the treatment of asthma is disclosed in US 6,201 ,027.
  • Suitable ⁇ 2 -adrenoreceptor agonists to be combined with orazipone include salbutamol, formoterol, fenoterol, procaterol, salmeterol, clenbuterol, bambuterol, bitolterol, carbuterol, hexoprenaline, ibuterol, pirbuterol, reproterol, sulfonterol, tulobuterol, clorprenaline, etafedrine, isoetharine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, terbutaline and the like and their salts, esters, solvates, isomers including enantiomers and diastereomers.
  • the preferred ⁇ 2 - adrenoreceptor agonist is formoterol or a pharmaceutically acceptable salt, hydrate or isomer thereof.
  • Preferred salt is formoterol fumarate, particularly in the form of dihydrate.
  • Other suitable salts include acid addition salts of inorganic and organic acids, e.g. chloride, sulphate, tartrate, citrate, lactate and succinate salts or solvates thereof.
  • Suitable corticosteroids to be combined with orazipone include beclometha- sone, budesonide, fluticasone, mometasone, betamethasone, triamcinolone, triamcinolone acetonide, flunisonide, ciclesonide, rofleponide, dexamethasone and the like and their salts and esters and solvates.
  • the preferred corticosteroid is budesonide.
  • One preferred inhalation medicament according to the invention comprises a combination of orazipone, a ⁇ 2 -adrenoreceptor agonist and a corticosteroid.
  • Another preferred inhalation medicament according to the invention comprises a combination of orazipone and a corticosteroid.
  • One particularly preferred inhalation medicament according to the invention comprises orazipone, formoterol or a salt or hydrate thereof and budesonide as a combined preparation.
  • Another particularly preferred inhalation medicament according to the invention comprises orazipone and budesonide as a combined preparation.
  • the combination of the invention is particularly useful in the treatment of asthma and other respiratory diseases, such as mild, moderate and severe asthma, allergic and non-allergic asthma, acute condition of asthma, intermittent asthma, episodes in chronic asthma, chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS).
  • the treatment may be symptomatic or prophylactic treatment.
  • the active ingredients of the combination are presented, separately or together, as a pharmaceutical formulation, optionally together with one or more pharmaceutically acceptable additive, diluent or carrier.
  • the combined preparation may contain the active ingredients in admixture, optionally together with one or more pharmaceutically acceptable additive, diluent or carrier.
  • one or more of the active ingredients may be presented in a separate pharmaceutical formulation such separate formulations being packaged as a combined preparation, optionally together a package insert instructing the patient to the correct use of the medicament.
  • the active ingredients are preferably in the form of micronized particles, preferably having mass median particle diameter of less than about 10 ⁇ m, suitably from about 1 to about 5 ⁇ m.
  • the amount of orazipone and ⁇ 2 -adrenoreceptor agonist and/or corticosteroid to be included in the composition is selected such as to achieve the desired therapeutical effect.
  • Suitable daily dose of orazipone is from about 100 ⁇ g to about 5000 ⁇ g, preferably from about 500 to about 2000 ⁇ g, depending on the age and weight of the patient and the severity and type of the disease.
  • Suitable daily dose of ⁇ 2 -adrenoreceptor agonist and corticosteroid vary with the particular compound, but daily amounts which are used in monotherapy are usually suitable.
  • formoterol fumarate is generally administered at a dose of from about 10 to about 150 ⁇ g daily, typically 12 or 24 ⁇ g twice daily.
  • Budesonide is generally administered at a dose of from about 200 to 1600 ⁇ g daily. The suitable amounts depend on the age and weight of the patient and the severity and type of the disease.
  • the medicament of the invention is in the form of a dry inhalation powder composition.
  • Such compositions may be prepared e.g. by agglomeration of the micronized particles of the active ingredients and possibly the micronized carrier particles using methods known in the art.
  • the dry inhalation powder composition is a mixture of the micronized particles of the active ingredients and carrier particles, the carrier particles being typically of coarser particle size.
  • a method of preparing such mixtures typically comprises adding the micronized active ingredients and part of the carrier particles into a blender and mixing until the powder mixture is homogenous. The mixture is then sieved to reduce the number of particle clusters present. Thereafter the rest of carrier particles is added and mixed until the powder is again homogenous.
  • Carbohydrates suitable for use as a dry powder carrier material include, for example, monosaccharides such as fructose, maltose or glucose; disaccharides such as lactose sucrose or trehalose; polysaccharides such as raffinose or melezitose; and alditols such as mannitol, xylitol, lactitol and the like.
  • Preferred carrier is lactose or glucose, lactose being most preferred.
  • the total amount of the active ingredients is about 0.05 - 50 % (w/w), preferably about 1 - 10 % (w/w), based on total weight of the composition.
  • the mass median particle diameter of the carrier is preferably between 5 and 150 ⁇ m, more preferably between 10 and 100 ⁇ m, most preferably between 15 and 80 ⁇ m.
  • the medicament may alternatively be in the form of a pressurized aerosol where fine drug particles are suspended in a propellant gas.
  • aerosol carriers include non-chlorofluorocarbon-based carriers such as HFA (hydrofluoro- alkane).
  • Pressurized aerosols can be prepared according to the methods well known in the art.
  • the medicament of the invention may also comprise additives such as solubilizers, stabilizers, flavouring agents, colorizing agents and preserving agents.
  • the medicament according to the invention is conveniently delivered by conventional means.
  • the medicament can be delivered from inhaler devices well known in the art such as pressurized metered dose inhalers, dry powder inhalers or nebulizers.
  • inhaler devices well known in the art such as pressurized metered dose inhalers, dry powder inhalers or nebulizers.
  • the medicament When the medicament is in the form of dry inhalation powder, it can be filled in e.g. capsules, cartridges, blister packs or a reservoir, from which the powder may be administered by means of a dry powder inhaler.
  • the separate formulations may be filled e.g. in a multi-reservoir type inhaler as described e.g. in WO 00/64519.
  • the formulations may be filled in separate inhalers packaged as a combined preparation.
  • the medicament according to the invention may be administered to a patient daily or periodically, e.g. one month on treatment and one month off treatment.
  • the medicament may be administered as divided doses from 1 to 4 doses a day.
  • the compositions of the invention comprise the active ingredients in amounts such that each actuation provides therapeutically effective dose.
  • the medicament suitably contains, per dose, from 6 to 50 ⁇ g, particularly from 12 to 24 ⁇ g, of formoterol fumarate dihydrate, from 50 to 600 ⁇ g, particularly from 100 to 400 ⁇ g, of budesonide and from 100 to 5000 ⁇ g, particularly from 200 to 2000 ⁇ g, of orazipone.
  • the medicament may contain, per dose, 12 ⁇ g of formoterol fumarate dihydrate, 200 ⁇ g of budesonide and 1000 ⁇ g of orazipone. Administration of one to two such doses by inhalation twice daily would be effective in most cases of moderate persistent asthma and is likely to suffice in many severe asthmatics, too.
  • An example of a particularly preferred embodiment of the invention is an inhalation medicament in the form of dry inhalation powder comprising a) formoterol or a pharmaceutically acceptable salt thereof having mass median particle diameter of less than about 10 ⁇ m, preferably from about 1 to about 5 ⁇ m; b) budesonide having mass median particle diameter of less than about 10 ⁇ m, preferably from about 1 to about 5 ⁇ m; c) orazipone having mass median particle diameter of less than about 10 ⁇ , preferably from about 1 to about 5 ⁇ m; and optionally d) carrier having mass median particle diameter between 5 and 150 ⁇ m, preferably between 10 and 100 ⁇ m, more preferably between 15 and 80 ⁇ m.
  • the amount of formoterol or a pharmaceutically acceptable salt thereof is preferably 0.01 - 5 %, more preferably 0.05 - 1 %, by weight of the composition; the amount of budesonide is preferably 0.1 - 50 %, more preferably 0.5 - 10 %, by weight of the composition; and the amount of orazipone is preferably 0.5 - 50 %, more preferably 1 - 20 %, by weight of the composition and the amount of the carrier is preferably 50 - 99.9 %, more preferably 90 - 99.5 %, by weight of the composition.
  • An example of another particularly preferred embodiment of the invention is an inhalation medicament in the form of dry inhalation powder comprising a) budesonide having mass median particle diameter of less than about 10 ⁇ m, preferably from about 1 to about 5 ⁇ m; c) orazipone having mass median particle diameter of less than about 10 ⁇ m, preferably from about 1 to about 5 ⁇ m; and optionally d) carrier having mass median particle diameter between 5 and 150 ⁇ m, preferably between 10 and 100 ⁇ m, more preferably between 15 and 80 ⁇ m.
  • Orazipone (micronized) 1000 ⁇ g
  • Orazipone (micronized) 1000 ⁇ g Lactose monohydrate Ph. Eur. 8 mg
  • Micronized active ingredients and part of the lactose were added into a blender. The powder mixture was mixed until it was homogenous. The mixture was then sieved to reduce the number of particle clusters present. Thereafter the rest of lactose was added and the powder was again mixed until it was homogenous. Powder was poured into the supply chamber of the multi-dose powder inhaler Easyhaler (Orion Corporation trademark) for a supply of 200 doses.
  • PBMC Peripheral blood mononuclear cells
  • Orazipone and Budesonide (Sigma Chemical, St Louis, MO, USA) were dissolved in DMSO and diluted prior to use in RPMI 1640. The final DMSO concentration was 0.05%.
  • RPMI-1640 fresh RPMI-1640 medium.
  • Cells were plated into 24 well culture plates in one ml RPMI-1640 at a concentration of 1 x 10" cells/ml.
  • Budesonide were added 30 min before the cells were stimulated with LPS (50 ng/ml) E. Coli (026:B6) (Sigma Chemical, St Louis, MO, USA). Orazipone was added 2h after LPS stimulation. After 24h stimulation, supernatants were collected and frozen at -75 °C until assayed for IL-8 using human ⁇ LISA kits from R&D Systems (Abingdon, UK). The cytokine levels were determined according to manufacturer's instructions.
  • Fig. 1 The effect of budesonide and orazipone and combination thereof on LPS-induced IL-8 production in peripheral blood mononuclear cells is summarized in Fig. 1.
  • the combination shows a superior and synergistic effect in inhibiting IL-8 production as compared to the effect of budesonide or orazipone alone.
  • the terms "Or.” and “Bude.” denote orazipone and budesonide, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An inhalation medicament comprising orazipone and a beta2-adrenoreceptor agonist and/or a corticosteroid as a combined preparation is provided. Optionally the medicament also comprises one or more pharmaceutically acceptable additive, diluents or carriers. The beta-2adrenoreceptor agonist the corticosteroid may comprise formoterol and budesonide.

Description

COMPOSITIONS FOR PULMONARY ADMINISTRATION
Field of the invention
The present invention relates to pharmaceutical compositions useful in the treatment of asthma and other respiratory disorders. More particularly, it relates to compositions comprising anti-inflammatory agent orazipone in combination with a β2-adrenoreceptor agonist and/or a corticosteroid.
Background of the invention
Asthma is currently treated with drugs that can be classified into two classes, namely anti-inflammatory agents and bronchodilators. Anti-inflammatory drugs such as corticosteroids and sodium cromoglycate do not relieve asthma symptoms once they occur, but rather they control the underlying inflammation. One of the drawbacks of anti-inflammatory drugs is that their onset of action is relatively slow. Therefore, patients often do not recognize any immediate therapeutic effects and tend to stop the medication. The acute asthma symptoms can be relieved by bronchodilators such as β2-adrenoreceptor agonists and theophylline. The short- acting inhaled β2-adrenoreceptor agonists, e.g. salbutamol and terbutaline, are important for an immediate symptomatic asthma relief, while long-acting β2- adrenoreceptor agonists, e.g. salmeterol, formoterol and procaterol, are important for treatment of moderate and severe asthma. However, there are currently still various debates on the safety of a regular use of β2-adrenoreceptor agonists as well as efficiency of long-acting β -adrenoreceptor agonists.
Inhalation has become the primary route of administration in the treatment of asthma and other respiratory diseases. This is because, besides providing direct access to the lungs, medication delivered through the respiratory tract provides rapid and predictable onset of action and requires lower dosages compared to the oral route. Typical delivery systems for inhalable drugs are the pressurized metered-dose inhaler (pMDI) comprising a suspension of fine drug particles in a propellant gas; the dry powder inhaler (DPI) comprising fine drug particles as dry powder typically admixed with coarser carrier or diluent such as lactose, and nebulizer comprising drug in aqueous solution or suspension. Inhalable combinations of an anti-inflamma- tory agent and a bronchodilator have been described e.g. in patent publications EP 416950, EP 416951 , WO 93/11773 and WO 98/15280.
Despite recent advances in the understanding and treatment of asthma, there are still problems related to dosing regimens and systemic effects of the anti-asthma drugs. Therefore improvements in the treatment of asthma and other respiratory disorders are desired.
Summary of the Invention
It has been found that an inhalation medicament comprising, as a combined preparation, orazipone and a β -adrenoreceptor agonist and/or a corticosteroid, provides improved disease control of asthma and other respiratory disorders.
Accordingly, the present invention provides an inhalation medicament comprising orazipone and a β2-adrenoreceptor agonist and/or a corticosteroid as a combined preparation.
The present invention also provides a method for treating asthma and other respiratory disorders which comprises the simultaneous, sequential or separate administration of an effective amount of orazipone and a β2-adrenoreceptor agonist and/or a corticosteroid.
The present invention also provides an inhaler device containing orazipone and β2-adrenoreceptor agonist and/or a corticosteroid as therapeutically active ingredients for pulmonary administration.
The active ingredients of the combination are preferably presented, separately or in admixture, as a pharmaceutical formulation together with one or more pharmaceutically acceptable additive, diluent or carrier.
The active ingredients are preferably provided as micronized particles, e.g. having mass median diameter of less than 10 μm. Preferably, the medicament is provided in the form of dry inhalation powder comprising the active ingredients in admixture with carrier particles. Brief Description of the Drawings
FIG. 1 shows the effect of budesonide and orazipone and combination thereof on LPS-induced IL-8 production in peripheral blood mononuclear cells.
Detailed Description of the Invention
Orazipone or 3-[(4-methylsulfonylphenyl)-methylene]-2,4-pentanedione is a locally acting anti-inflammatory agent that decomposes in the blood circulation. A method for preparing orazipone for the treatment of inflammatory bowel disease is described in European Patent No. 440324 Bl. A powdered inhalation composition of orazipone for the treatment of asthma is disclosed in US 6,201 ,027.
Suitable β2-adrenoreceptor agonists to be combined with orazipone include salbutamol, formoterol, fenoterol, procaterol, salmeterol, clenbuterol, bambuterol, bitolterol, carbuterol, hexoprenaline, ibuterol, pirbuterol, reproterol, sulfonterol, tulobuterol, clorprenaline, etafedrine, isoetharine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, terbutaline and the like and their salts, esters, solvates, isomers including enantiomers and diastereomers. The preferred β2- adrenoreceptor agonist is formoterol or a pharmaceutically acceptable salt, hydrate or isomer thereof. Preferred salt is formoterol fumarate, particularly in the form of dihydrate. Other suitable salts include acid addition salts of inorganic and organic acids, e.g. chloride, sulphate, tartrate, citrate, lactate and succinate salts or solvates thereof.
Suitable corticosteroids to be combined with orazipone include beclometha- sone, budesonide, fluticasone, mometasone, betamethasone, triamcinolone, triamcinolone acetonide, flunisonide, ciclesonide, rofleponide, dexamethasone and the like and their salts and esters and solvates. The preferred corticosteroid is budesonide.
One preferred inhalation medicament according to the invention comprises a combination of orazipone, a β2-adrenoreceptor agonist and a corticosteroid. Another preferred inhalation medicament according to the invention comprises a combination of orazipone and a corticosteroid. One particularly preferred inhalation medicament according to the invention comprises orazipone, formoterol or a salt or hydrate thereof and budesonide as a combined preparation. Another particularly preferred inhalation medicament according to the invention comprises orazipone and budesonide as a combined preparation.
The combination of the invention is particularly useful in the treatment of asthma and other respiratory diseases, such as mild, moderate and severe asthma, allergic and non-allergic asthma, acute condition of asthma, intermittent asthma, episodes in chronic asthma, chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS). The treatment may be symptomatic or prophylactic treatment.
The active ingredients of the combination are presented, separately or together, as a pharmaceutical formulation, optionally together with one or more pharmaceutically acceptable additive, diluent or carrier. For example, the combined preparation may contain the active ingredients in admixture, optionally together with one or more pharmaceutically acceptable additive, diluent or carrier. Alternatively, one or more of the active ingredients may be presented in a separate pharmaceutical formulation such separate formulations being packaged as a combined preparation, optionally together a package insert instructing the patient to the correct use of the medicament.
The active ingredients are preferably in the form of micronized particles, preferably having mass median particle diameter of less than about 10 μm, suitably from about 1 to about 5 μm.
The amount of orazipone and β2-adrenoreceptor agonist and/or corticosteroid to be included in the composition is selected such as to achieve the desired therapeutical effect.
Suitable daily dose of orazipone is from about 100 μg to about 5000 μg, preferably from about 500 to about 2000 μg, depending on the age and weight of the patient and the severity and type of the disease.
Suitable daily dose of β2-adrenoreceptor agonist and corticosteroid vary with the particular compound, but daily amounts which are used in monotherapy are usually suitable. For example, formoterol fumarate is generally administered at a dose of from about 10 to about 150 μg daily, typically 12 or 24 μg twice daily. Budesonide is generally administered at a dose of from about 200 to 1600 μg daily. The suitable amounts depend on the age and weight of the patient and the severity and type of the disease.
Preferably the medicament of the invention is in the form of a dry inhalation powder composition. Such compositions may be prepared e.g. by agglomeration of the micronized particles of the active ingredients and possibly the micronized carrier particles using methods known in the art.
It is particularly preferred that the dry inhalation powder composition is a mixture of the micronized particles of the active ingredients and carrier particles, the carrier particles being typically of coarser particle size. A method of preparing such mixtures typically comprises adding the micronized active ingredients and part of the carrier particles into a blender and mixing until the powder mixture is homogenous. The mixture is then sieved to reduce the number of particle clusters present. Thereafter the rest of carrier particles is added and mixed until the powder is again homogenous.
Particularly preferred carrier materials in dry inhalation powder compositions are carbohydrates. Carbohydrates suitable for use as a dry powder carrier material include, for example, monosaccharides such as fructose, maltose or glucose; disaccharides such as lactose sucrose or trehalose; polysaccharides such as raffinose or melezitose; and alditols such as mannitol, xylitol, lactitol and the like. Preferred carrier is lactose or glucose, lactose being most preferred.
If the medicament contains a carrier, e.g. lactose, the total amount of the active ingredients is about 0.05 - 50 % (w/w), preferably about 1 - 10 % (w/w), based on total weight of the composition.
The mass median particle diameter of the carrier is preferably between 5 and 150 μm, more preferably between 10 and 100 μm, most preferably between 15 and 80 μm.
The medicament may alternatively be in the form of a pressurized aerosol where fine drug particles are suspended in a propellant gas. Examples of aerosol carriers include non-chlorofluorocarbon-based carriers such as HFA (hydrofluoro- alkane). Pressurized aerosols can be prepared according to the methods well known in the art. The medicament of the invention may also comprise additives such as solubilizers, stabilizers, flavouring agents, colorizing agents and preserving agents.
For administration by inhalation, the medicament according to the invention is conveniently delivered by conventional means. For example, the medicament can be delivered from inhaler devices well known in the art such as pressurized metered dose inhalers, dry powder inhalers or nebulizers. When the medicament is in the form of dry inhalation powder, it can be filled in e.g. capsules, cartridges, blister packs or a reservoir, from which the powder may be administered by means of a dry powder inhaler.
In case, one or more of the active ingredients are in separate pharmaceutical formulations, the separate formulations may be filled e.g. in a multi-reservoir type inhaler as described e.g. in WO 00/64519. Alternatively, the formulations may be filled in separate inhalers packaged as a combined preparation.
The medicament according to the invention may be administered to a patient daily or periodically, e.g. one month on treatment and one month off treatment. The medicament may be administered as divided doses from 1 to 4 doses a day.
Suitably, the compositions of the invention comprise the active ingredients in amounts such that each actuation provides therapeutically effective dose. For example, the medicament suitably contains, per dose, from 6 to 50 μg, particularly from 12 to 24 μg, of formoterol fumarate dihydrate, from 50 to 600 μg, particularly from 100 to 400 μg, of budesonide and from 100 to 5000 μg, particularly from 200 to 2000 μg, of orazipone.
Thus, the medicament may contain, per dose, 12 μg of formoterol fumarate dihydrate, 200 μg of budesonide and 1000 μg of orazipone. Administration of one to two such doses by inhalation twice daily would be effective in most cases of moderate persistent asthma and is likely to suffice in many severe asthmatics, too.
An example of a particularly preferred embodiment of the invention is an inhalation medicament in the form of dry inhalation powder comprising a) formoterol or a pharmaceutically acceptable salt thereof having mass median particle diameter of less than about 10 μm, preferably from about 1 to about 5 μm; b) budesonide having mass median particle diameter of less than about 10 μm, preferably from about 1 to about 5 μm; c) orazipone having mass median particle diameter of less than about 10 μ , preferably from about 1 to about 5 μm; and optionally d) carrier having mass median particle diameter between 5 and 150 μm, preferably between 10 and 100 μm, more preferably between 15 and 80 μm.
In the above embodiment, the amount of formoterol or a pharmaceutically acceptable salt thereof is preferably 0.01 - 5 %, more preferably 0.05 - 1 %, by weight of the composition; the amount of budesonide is preferably 0.1 - 50 %, more preferably 0.5 - 10 %, by weight of the composition; and the amount of orazipone is preferably 0.5 - 50 %, more preferably 1 - 20 %, by weight of the composition and the amount of the carrier is preferably 50 - 99.9 %, more preferably 90 - 99.5 %, by weight of the composition.
An example of another particularly preferred embodiment of the invention is an inhalation medicament in the form of dry inhalation powder comprising a) budesonide having mass median particle diameter of less than about 10 μm, preferably from about 1 to about 5 μm; c) orazipone having mass median particle diameter of less than about 10 μm, preferably from about 1 to about 5 μm; and optionally d) carrier having mass median particle diameter between 5 and 150 μm, preferably between 10 and 100 μm, more preferably between 15 and 80 μm.
The invention is further illustrated by the following examples and experiments, which are not meant to limit the scope of the invention.
Example 1. Dry inhalation powder (per dose)
Formoterol fumarate dihydrate (micronized) 12 μg
Budesonide (micronized) 200 μg
Orazipone (micronized) 1000 μg
Lactose monohydrate Ph. Eur. 8 mg Example 2. Dry inhalation powder (per dose)
Budesonide (micronized) 200 μg
Orazipone (micronized) 1000 μg Lactose monohydrate Ph. Eur. 8 mg
Micronized active ingredients and part of the lactose were added into a blender. The powder mixture was mixed until it was homogenous. The mixture was then sieved to reduce the number of particle clusters present. Thereafter the rest of lactose was added and the powder was again mixed until it was homogenous. Powder was poured into the supply chamber of the multi-dose powder inhaler Easyhaler (Orion Corporation trademark) for a supply of 200 doses.
Experiments
Methods
Peripheral blood mononuclear cells (PBMC)
Leukocyte-rich buffy coats were obtained from the Finnish Red Cross Blood
Transfusion Service (Helsinki, Finland) and mononuclear cells were isolated by centrifugation on Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). After being washed, the cells were resuspended in RPMI-1640 medium containing 25 mM Hepes (Life Technologies, Paisley, UK) 10% heat-inactivated human AB serum (The Finnish Red Cross Blood Transfusion Service, Helsinki, Finland), 2mM L-Glutamine (Sigma Chemical, St Louis, MO, USA) and antibiotics: 50U penicillin- 50μg/ml (Sigma Chemical). Resuspended cells were stored at 4°C overnight.
Test compounds
Orazipone and Budesonide (Sigma Chemical, St Louis, MO, USA) were dissolved in DMSO and diluted prior to use in RPMI 1640. The final DMSO concentration was 0.05%.
Measurement of cytokine production
On day two, the cells were sentrifuged and resuspended in fresh RPMI-1640 medium. Cells were plated into 24 well culture plates in one ml RPMI-1640 at a concentration of 1 x 10" cells/ml. Budesonide were added 30 min before the cells were stimulated with LPS (50 ng/ml) E. Coli (026:B6) (Sigma Chemical, St Louis, MO, USA). Orazipone was added 2h after LPS stimulation. After 24h stimulation, supernatants were collected and frozen at -75 °C until assayed for IL-8 using human ΕLISA kits from R&D Systems (Abingdon, UK). The cytokine levels were determined according to manufacturer's instructions. The effect of budesonide and orazipone and combination thereof on LPS-induced IL-8 production in peripheral blood mononuclear cells is summarized in Fig. 1. The combination shows a superior and synergistic effect in inhibiting IL-8 production as compared to the effect of budesonide or orazipone alone. The terms "Or." and "Bude." denote orazipone and budesonide, respectively.

Claims

Claims
1. Inhalation medicament comprising orazipone and β2-adrenoreceptor agonist and/or a corticosteroid as a combined preparation.
2. Inhalation medicament according to claim 1 , wherein the β2- adrenoreceptor agonist is salbutamol, formoterol, fenoterol, procaterol, salmeterol, clenbuterol, bambuterol, bitolterol, carbuterol, hexoprenaline, ibuterol, pirbuterol, reproterol, sulfonterol, tulobuterol, clorprenaline, etafedrine, isoetharine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, terbutaline or their salt, ester, solvate or isomer including enantiomers and diastereomers.
3. Inhalation medicament according to claim 2, wherein the β2- adrenoreceptor agonist is formoterol or a pharmaceutically acceptable salt or ester or hydrate thereof.
4. Inhalation medicament according to any of claims 1 - 3, wherein the corticosteroid is beclomethasone, budesonide, fluticasone, mometasone, betamethasone, triamcinolone, triamcinolone acetonide, flunisonide, ciclesonide, rofleponide, dexamethasone or their salt, esters or solvate.
5. Inhalation medicament according to claim 4, wherein the corticosteroid is budesonide.
6. Inhalation medicament comprising orazipone and a corticosteroid as a combined preparation.
7. Inhalation medicament according to claim 6, wherein the corticosteroid is beclomethasone, budesonide, fluticasone, mometasone, betamethasone, triamcinolone, triamcinolone acetonide, flunisonide, ciclesonide, rofleponide, dexamethasone or their salt, esters or solvate.
8. Inhalation medicament according to claim 7, wherein the corticosteroid is budesonide.
9. Inhalation medicament according to any of claims 1 to 8, wherein the active ingredients are in the form of micronized particles having mass median diameter of less than 10 μm.
10. Inhalation medicament according claim 9, in the form of dry inhalation powder.
11. Inhalation medicament according to claim 10, wherein the active ingredients are in admixture with a carrier.
12. Inhalation medicament according to claim 1 1, wherein the carrier is lactose.
13. Inhaler device containing orazipone and β2-adrenoreceptor agonist and/or a corticosteroid as therapeutically active ingredients for pulmonary administration.
14. Inhaler device according to claim 13, which is a dry powder inhaler.
15. A method for treating asthma and other respiratory disorders which comprises the simultaneous, sequential or separate administration of an effective amount of orazipone and a β2-adrenoreceptor agonist and/or a corticosteroid.
PCT/FI2003/000054 2002-01-23 2003-01-22 Compositions for pulmonary administration WO2003061637A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002473697A CA2473697A1 (en) 2002-01-23 2003-01-22 Compositions for pulmonary administration
EP03700322A EP1476142A1 (en) 2002-01-23 2003-01-22 Compositions for pulmonary administration
US10/502,087 US20050143361A1 (en) 2002-01-23 2003-01-22 Compositions for pulmonary administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20020126A FI20020126A0 (en) 2002-01-23 2002-01-23 Compositions for pulmonary administration
FI20020126 2002-01-23

Publications (1)

Publication Number Publication Date
WO2003061637A1 true WO2003061637A1 (en) 2003-07-31

Family

ID=8562889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2003/000054 WO2003061637A1 (en) 2002-01-23 2003-01-22 Compositions for pulmonary administration

Country Status (5)

Country Link
US (1) US20050143361A1 (en)
EP (1) EP1476142A1 (en)
CA (1) CA2473697A1 (en)
FI (1) FI20020126A0 (en)
WO (1) WO2003061637A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064014A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
WO2000001667A1 (en) * 1998-07-01 2000-01-13 Orion Corporation SUBSTITUTED β-DIKETONES AND THEIR USE
WO2003002111A1 (en) * 2001-06-28 2003-01-09 Orion Corporation Inhalation particles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064014A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
WO2000001667A1 (en) * 1998-07-01 2000-01-13 Orion Corporation SUBSTITUTED β-DIKETONES AND THEIR USE
WO2003002111A1 (en) * 2001-06-28 2003-01-09 Orion Corporation Inhalation particles

Also Published As

Publication number Publication date
US20050143361A1 (en) 2005-06-30
EP1476142A1 (en) 2004-11-17
FI20020126A0 (en) 2002-01-23
CA2473697A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
CN101181263B (en) Treatment of respiratory diseases
US9549936B2 (en) Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide
PT1158970E (en) Combinations of formoterol and a tiotropium salt
KR20220045214A (en) Pharmaceutical composition comprising ensifentrine
WO2002028368A1 (en) New combination for the treatment of asthma
US20140342001A1 (en) Medicaments
US20040101482A1 (en) Medicaments
EA015353B1 (en) Use of tiotropium salts in the treatment of moderate persistent asthma
KR20100072295A (en) Combination therapy
EP2682099A1 (en) Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists
US20050143361A1 (en) Compositions for pulmonary administration
EP3842031A1 (en) New therapeutic inhalation system providing reduced dose of fluticasone propionate and salmeterol xinafoate with improved efficacy and safety profile
JP2017530988A (en) Formulation containing tiotropium, amino acid and acid, and method thereof
US20220331244A1 (en) Novel carrier particles for dry powder formulations for inhalation
AU2002231939A1 (en) Bimodal dry powder formulation for inhalation
KR20160038767A (en) Dry powder for inhalation formulation with improved stability of combined active ingredients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2473697

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003700322

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003700322

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10502087

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003700322

Country of ref document: EP